LITMIR.BIZ

Скачать книгу

award-winning weekly newsletter featuring the latest breakthroughs in life extension and life enhancement Global media reach: •Major print, tv, radio placements that raise the profile of anti-aging medicine: past placements include BBC (British Broadcast Channel), The O’Reilly Factor, Lifetime, 48 Hours, 20/20, CBS Evening News, Oprah Winfrey Show, New York Times, Los Angeles Times, Chicago Tribune, CNN, USA Today, Forbes, Business Week, Investor's Business Daily, Smart Money, WebMD and HealthScout (partial list) •Syndicated column published in magazines in 6 countries Excellence in publishing: •Publishes books for consumer audience that raise the awareness of anti-aging medicine in the general public, with over 2 million copies in-print •Publishes titles for clinicians, researchers, government agencies, and academic institutions Videos: 2,000+ YouTube anti-aging videos by/on A4M

      ACCOMPLISHMENTS

      A4M serves as an advocate for the new clinical specialty of anti-aging medical science and acts as a conduit to physicians, scientists, and the educated public who wish to benefit from the almost daily breakthroughs in biotechnology which promise both a greater quality as well as quantity of life. The A4M is the:

      •First to create the anti-aging medical movement.

      •Founder of the world’s fastest-growing medical specialty.

      •Leading provider of university academic co-sponsored medical education in the field.

      •Recognized leadership for a $295 billion marketplace

      Nearly 3 decades ago, the founding members of the A4M predicted the shift in the global demographics towards a worldwide greying trend, and the organization forged a model for clinical healthcare to advance preventive healthcare by applying cutting-edge diagnostic and therapeutic technologies. An array of life-enhancing, life-extending achievements for human longevity has since resulted. World-renowned speakers at the A4M’s Annual Congresses on Anti-Aging Medicine have debuted breakthrough findings that include:

      Table 2. Preventative Medical Breakthroughs Based in Anti-Aging Science (partial list)

2015:
	Microbiome in brain health [Perlmutter]
	Cardiac-neurological-immune connection [Houston]
2010:
	Concussion in Neurodegenerative Disease [Maroon]
2007:
	Traumatic Brain Injury (TBI) & hormone dysregulation [Gordon]
2006:
	Phytonutrients for prevention of atherosclerosis [Siegel]
2005:
	Inflammation in neurodegenerative disorders [Perlmutter]
	Fatty acids for cardiovascular health [Rothenberg]
2003:
	Inflammation in cardiovascular disease [Sinatra]
	Vaccine for Alzheimer’s Disease [Da Silva]
1999:
	Insulin in aging [Sears]
	Calcium for the prevention and treatment of osteoporosis [Fujita]
	Thyroid dysfunction in aging [Rouzier; Hertoghe]
1998:
	Natural compounds for cancer prevention & therapy [Holt; Lane]
	CoEnzyme Q10 & cardiovascular disease [Sinatra]
	Noninvasive scans for brain assessment [Braverman]
1997:
	Homocysteine as a marker for heart disease [Fox]
	Cerebrovascular assessment & treatment [Braverman; Bodo]
1996:
	Importance of growth hormone in adulthood [Hertoghe]
	DHEA [Regelson]
	Molecular nanotechnology in medicine [Merkle]
1995:
	Melatonin as cancer-fighting compound [Lissoni]
	Nutritional therapies for aging-related memory decline [Khalsa; Kidd]
	Reversal of skin aging with non-/minimally-invasive techniques [Giacomoni]

      ADOPTION

      Today, multinational companies are pouring billions of dollars into anti-aging medical technologies. In particular, Silicon Valley has engaged significant resources: each of these megacorporations proudly equates themselves with “anti-aging.” As such, the phrase “anti-aging” is now poised for transformation from a disparaged term to one of prestige and dominance.

      Google backs privately held 23andMe, which offers a DNA test for consumers who can secure genetic reports and ancestry-related data. In 2013 by Google’s CEO and co-founder, Larry Page – 40 years old at the time, founded Calico (California Life Company) with $1 billion in start-up funding. Describing its goal as “focusing on the challenge of aging and associated diseases.” Page has observed that: “With some longer term, moonshot thinking around healthcare and biotechnology, I believe we can improve millions of lives.”¹ Calico is headed by Art Levinson, former CEO of Genetech, a highly successful biotech company specializing in cancer therapies.

      In mid-2014, Calico forged a 10-year R&D collaboration deal with AbbVie Inc., a major US drugmaker (notably, Humira®, a rheumatoid arthritis biologic).² Each company is reported to invest an initial $250 million, with a possible additional $500 million in the future. Using this funding, Calico will use its scientific expertise to establish

Скачать книгу